Non-Hodgkin Lymphoma (NHL)

Latest News

There remains a need for more diagnostic accuracy in cases of soft tissue NHL | image credit: phonlamaiphoto - stock.adobe.com

MRI, sIL-2R Combination Showcases Great Diagnostic Accuracy for Soft Tissue NHL

January 27th 2025

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.

FDA approval | Image Credit: © wladimir1804 - stock.adobe.com

FDA Grants 2 Traditional Approvals for Acalabrutinib

By Maggie L. Shaw

January 17th 2025

Genetic analysis-angellodeco-stock.adobe.com

The Role of Geriatric Assessment Tools in Enhancing Oncology Care: ASH 2024

By Giuliana Grossi

December 18th 2024

Senior elderly older man smiling with nurse - Beaunitta Van Wyk:peopleimages.com - stock.adobe.com

Fixed-Duration Epcoritamab Is Active, Safe in Older Patients With Newly Diagnosed LBCL

December 17th 2024

non-Hodgkin lymphoma | Image Credit: © jarun011-stock.adobe.com

Epcoritamab Offers Durable Results in Relapsed B-Cell Lymphoma

By Maggie L. Shaw

December 9th 2024

Continuing Medical Education

January 28th 2025

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer

January 28th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

January 28th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology

January 28th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

More News

Photomicrograph of a diffuse large B-cell lymphoma | Image Credit: ©DavidALitman - stock.adobe.com

May 16th 2024

Patient/Physician Teamwork: Treating a Rare Oral Presentation of DLBCL

Gayle Turim Dickstein

A very unusual case of lip-based diffuse large B-cell lymphoma (DLBCL) was treated successfully thanks to prompt diagnosis and chemotherapy treatments.

Health costs | Image credit: utah51 - stock.adobe.com

May 8th 2024

Study: Care Costs for R/R DLBCL Increase With Each Line of Therapy

Jared Kaltwasser

New therapies are helping patients, but are also driving up overall costs of care.

Lymphoma graphic | Image Credit: © MP Studion - stock.adobe.com

May 2nd 2024

Much-Improved Outcomes for Follicular Lymphoma Transformed to DLBCL in the Rituximab Era, Study Finds

Gayle Turim Dickstein

Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago.

IV chemotherapy | Image Credit: Aidman - stock.adobe.com

April 24th 2024

Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL

Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).

Doctors discussing a case | Image Credit: DelmaineDonson - stock.adobe.com

April 18th 2024

Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes

Kimberly Rath, PharmD

A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.

Liquid biopsy | Image Credit: ArtemisDiana - stock.adobe.com

April 13th 2024

Liquid Biopsy Whole-Genome Sequencing Optimizes MRD Detection in DLBCL

Using the newly created MAESTRO-Pool tool, whole genome sequencing revealed DNA that could be used to more effectively detect minimum residual disease (MRD) in patients who have diffuse large B-cell lymphoma (DLBCL).

Lymphoma diagnosis | Image Credit: Vitalii Vodolazskyi - stock.adobe.com

April 9th 2024

CAR T-Cell Therapy Effective in Older Patients With DLBCL

Overall survival and complete response rates were comparable across a younger and an older cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Malignant effusion cytology microscopic image of diffuse large B-cell lymphoma a type of non Hodgkin lymphoma | Image credit: David A Litman - stock.adobe.com

April 1st 2024

Older Patients With DLBCL Face Poor Overall Survival, High Costs With R-GemOx Treatment

Treatment with R-GemOx was associated with significant health care resource utilization, high costs surrounding treatment, and low overall survival in elderly patients with diffuse large B-cell lymphoma (DLBCL).

FDA | Image credit: wladimir1804 - stock.adobe.com

March 25th 2024

FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma, R/R DLBCL

The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).

Magnified image of a cytokine storm | Image Credit: © nobeastsofierce - stock.adobe.com

March 19th 2024

Bispecific Antibodies Represent DLBCL Treatment Breakthrough

Analysis of single-agent, combination, and novel bispecific antibodies revealed a positive landscape of treatment for patients with diffuse large B-cell lymphoma (DLBCL).

Photomicrograph of a diffuse large B-cell lymphoma a type of non-Hodgkin lymphoma | Image Credit: DavidALitman - stock.adobe.com

March 15th 2024

Radiotherapy May Boost Survival for Certain Patients With DLBCL

Jared Kaltwasser

Patients had a lower risk of their diffuse large B-cell lymphoma (DLBCL) progressing if they had consolidative radiotherapy, a new report shows.

Patient in the hospital - Tyler Olson -stock.adobe.com.jpg

March 9th 2024

Predictive Model Can Assess Risk of Febrile Neutropenia in Patients Undergoing Chemotherapy for DLBCL

Investigators used a predictive model factoring in lymphopenia, elevated SIL2R level, extranodal involvement, and a positive hepatitis panel to determine risk for febrile neutropenia among patients with diffuse large B-cell lymphoma (DLBCL).

Case study graphic | Image credit: onephoto - stock.adobe.com

February 29th 2024

R-CHOP Leads to Positive Outcome in Rare Case of Collision Lymphoma

Jared Kaltwasser

The patient had both classical Hodgkin lymphoma and diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma - David A Litman - stock.adobe.com

February 28th 2024

Review Highlights Potential for Bispecific Antibodies in DLBCL

Investigators are optimistic about bispecific antibodies (BsAbs) for patients with diffuse large B-cell lymphoma (DLBCL), especially the possibility of combining different BsAbs with distinct targets for stronger treatment outcomes.

Doctor checking an older mans lungs | Image credit: DC Studio-stock.adobe.com

February 23rd 2024

Case of Primary Hepatic DLBCL Following COVID-19 Raises Questions About Possible Links

Jared Kaltwasser

Other viral infections, including Epstein-Barr virus and hepatitis C, have already been linked with primary hepatic lymphoma, the authors said.

Rituximab | Image credit: MQ-Illustrations - stock.adobe.com

February 20th 2024

Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL

Cameron Santoro

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

CAR T cell therapy rendering | Image Credit: © AIGen - stock.adobe.com

February 12th 2024

Meta-Analysis Highlights Differing CAR T Outcomes, Toxicities in Relapsed or Refractory DLBCL

A real-world comparison of 2 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel and tisagenlecleucel—suggests the former is associated with better efficacy but higher toxicity.

A scientist working with microfluidic devices | Image credit: Наталья Евтехова - stock.adobe.com

February 4th 2024

Study: Microfluid Platform Can Help Screen Novel DLBCL Therapies

Jared Kaltwasser

The authors say their 3D model improves on results using traditional 2-dimensional approaches.

stem cell transplant text write on blackboard | Image credit: flytoskyft11 - stock.adobe.com

January 30th 2024

Retrospective Analysis Suggests Allo-HSCT Feasible for R/R DLBCL After CAR T Failure

Jared Kaltwasser

Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.

Patient and doctor | Image Credit: © DragonImages - stock.adobe.com

January 26th 2024

Case Report Highlights Case of Distinct DLBCLs in a Single Patient

Jared Kaltwasser

The authors suggest the phenomenon of 2 mutationally distinct diffuse large B-cell lymphomas (DLBCLs) might be more common than currently understood.

January 25th 2024

What We’re Reading: ACA Sign-Up Surge; Hospitals Fight Climate Change; Secondary Cancers, CAR T Link

A record 21.3 million people signed up for health insurance this year using the Affordable Care Act (ACA) marketplaces; nearly 80% of health care providers think it is important for their hospital to minimize its environmental impact; the FDA noted a potential link between CAR-T products and the development of T-cell cancer.

Data analytics | Image Credit: NicoElNino - stock.adobe.com

January 24th 2024

In DLBCL, Refining Patient Stratification an Ongoing Project

Jared Kaltwasser

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states.

Ibrutinib | Image Credit: CLShebley

January 22nd 2024

Ibrutinib Plus R-CHOP Cost-Effective for Young Patients With ABC-DLBCL

Jared Kaltwasser

Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found.

Health care costs graphic | Image credit: wladimir1804 – stock.adobe.com

January 19th 2024

Study Highlights Treatment Patterns, Costs for DLBCL Not Treated With Stem Cell Transplant

Hayden E. Klein

Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.

January 12th 2024

Next Frontier of Precision Hematology Uses Patient Tissue to Find a Therapy Match

Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R/R Follicular Lymphoma

January 8th 2024

Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R/R Follicular Lymphoma

Lymphoma cells | Image credit: LASZLO - stock.adobe.com

September 22nd 2023

Salvage RT Shows Local Control in LBCL After CAR T-Cell Therapy Failure

Salvage radiation therapy (RT) showed efficacy in local control of relapsed or refractory large B-cell lymphoma (LBCL) following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy failure.

Diffuse large B-cell lymphoma | Image credit: David A Litman - stock.adobe.com

September 21st 2023

Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL

Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.

CT machine | Image credit: MyPixelArtStudios - stock.adobe.com

September 15th 2023

Novel PET-Based Radiomics Signature Predicts CAR T Efficacy in DLBCL

A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Blood cells | Image credit: Катерина Євтехова - stock.adobe.com

September 7th 2023

Review Highlights Knowledge Gaps in Lymphoma Treatment Outcomes in AYAs

The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions